Navigation Links
Increasing Diagnosis Rates and Growing Use of Key Agents Such as Pfizer's Lyrica Will Drive Eight Percent Annual Growth in the Fibromyalgia Drug Market Through 2018
Date:7/13/2009

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased use of key agents such as Pfizer's Lyrica, Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar/Ariclaim and Forest Laboratories/Cypress Bioscience's Savella will drive eight percent annual growth in the fibromyalgia market through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Fibromyalgia also finds that improved diagnosis of the disorder and an expanding drug-treated population will be major market drivers over the next decade, particularly in the U.S. where the greatest growth in diagnosis rates is expected to occur. In the world's major markets, the U.S. accounted for nearly 80 percent of fibromyalgia drug sales in 2008 and will continue to account for more than two-thirds of fibromyalgia drug sales through 2018. Expansion of the market in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

"Uptake of Lyrica and Cymbalta/Xeristar/Ariclaim will be limited in Europe because both agents received a negative opinion from European regulatory authorities for approval for fibromyalgia," said Decision Resources Analyst Andrea Buurma, B.A. "Although the decision for Savella has not been made yet, regulators' initial refusal to recommend Lyrica's and Cymbalta's marketing authorizations for fibromyalgia indicates more rigorous standards in this region -- it is not clear whether Savella will be able to meet these standards."

The report also finds that, owing to its status as the first-ever approved agent for fibromyalgia and its favorable safety and tolerability profile, Lyrica will remain the dominant U.S. patient and market share leader through 2018 for fibromyalgia treatment. In the U.S., nearly half of the drug-treated fibromyalgia population received Lyrica in 2008, and this patient share will not change through 2018.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Fibromyalgia: Assessing Current and Future Opportunities in an Expanding Drug-Treated Population. This webinar will be held on Tuesday, July 28 at 2 p.m. EDT. For more information, please contact Gisselle Morales at 781-296-2691 or email her at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Planning for 2020: increasing elderly population poses huge challenges in cancer care
3. US hospitals report infections increasing in frequency and cost
4. Increasing young adult smoking linked to smoking in movies
5. Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
6. New Report: Increasing Oregons Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
7. New Report: Increasing Marylands Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
8. Increasing genetic diversity of HIV in the US
9. Studies Show Importance of Language Services on Reducing Disparities, Increasing Quality of Patient Care
10. Kidney Disease Increasing in U.S.
11. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... today announced that it has become the Official Technology Partner of North Country ... AES (Advanced Event Systems) volleyball software, along with providing sport management software ...
(Date:8/21/2017)... ... ... PIXACORE , an independent full-service agency with a decade of experience ... year by MM&M. , This is the first time PIXACORE has made the Top ... PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic transformation. ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across the ... as the moon moves between the sun and Earth. This rare event will be magnificent ... can help keep you safe on the road during the total eclipse of the sun. ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer of ... has purchased the 7D Surgical System to support its strategic ... Washington D.C. and Virginia.  7D Surgical has entered ... many of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
Breaking Medicine Technology: